Celltrion will cancel treasury shares worth 203.3 billion won ($140 million) to enhance shareholder value, the Korean drugmaker said on Friday.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Inflammatory bowel disease is a diverse disease that affects people all over the globe. This diversity in setting and treatment options makes it difficult for researchers to estimate the exact cost of ...

To read all of these articles and more, visit centerforbiosimilars.com.

South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of ...